Ampyra approved to improve walking in multiple sclerosis patients

AMPRYA (dalfampridine) 10mg extended release tablets by Elan and Acorda Therapeutics
AMPRYA (dalfampridine) 10mg extended release tablets by Elan and Acorda Therapeutics
The FDA has approved Ampyra (dalfampridine extended-release tablets, from Elan and Acorda Therapeutics) to improve walking in adults with multiple sclerosis (MS). Ampyra exerts its effects by closing the exposed potassium channels on demyelinated axons which cause nerve impulse “short circuits”, subsequently improving nerve impulse conduction. In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with placebo.

For more information call (914) 347-4300 or visit www.acorda.com.